The CDKN1A gene encoding a cell cycle inhibitor, p21(WAF1/CIP1), is located in the systemic lupus erythematosus (SLE) susceptibility locus on chromosome 6p21.2. Decreased cellular levels of p21 are associated with SLE. Here, we examine four single-nucleotide polymorphisms (SNPs) within the promoter and two in the first intron of CDKN1A for association with SLE susceptibility. A comparison of 742 Korean SLE patients with 1017 controls disclosed that one SNP (rs762624 C4A at position À899), located at a putative Myb-binding site in the promoter, was associated with SLE susceptibility (P ¼ 0.00047). This association was independent of the SLE-association signal of HLA-DRB1 on 6p21.3, as it was significant after adjustment for SLE-risk DRB1 alleles (P ¼ 0.0012). The same SNP was associated with lupus nephritis (P ¼ 0.000014). The risk allelecarrying promoter sequence displayed B15% lower activity than the non-risk sequence upon fusion to the luciferase gene (P ¼ 0.025). Endogenous CDKN1A mRNA levels measured in Epstein-Barr virus-transformed B cells established from 16 control subjects were linearly correlated with a decreasing copy number of the risk allele (P ¼ 0.024). Accordingly, we conclude that the minor allele A at À899 of CDKN1A is associated with increased susceptibility to SLE and lupus nephritis, and decreased cellular levels of p21.